INS018_055
- Generic Name
- INS018_055
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C27H30FN7O
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Associated Conditions
- -
- Associated Therapies
- -
Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-08-04
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- InSilico Medicine Hong Kong Limited
- Target Recruit Count
- 60
- Registration Number
- NCT05975983
- Locations
- πΊπΈ
Bogan Sleep Consultants, LLC, Columbia, South Carolina, United States
πΊπΈKeck School of Medicine of USC, Los Angeles, California, United States
πΊπΈUniversity of Oklahoma Health Sciences Center (OUHSC), Oklahoma City, Oklahoma, United States
Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Phase 2
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-07-11
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- InSilico Medicine Hong Kong Limited
- Target Recruit Count
- 70
- Registration Number
- NCT05938920
- Locations
- π¨π³
Anhui Chest Hospital, Hefei, Anhui, China
π¨π³The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
π¨π³Peking University Shougang Hospital, Beijing, Beijing, China
A Phase 1, Evaluate the Safety, Tolerability, and Pharmacokinetics of INS018_055 in Healthy Subjects
- First Posted Date
- 2021-12-13
- Last Posted Date
- 2023-06-29
- Lead Sponsor
- InSilico Medicine Hong Kong Limited
- Target Recruit Count
- 78
- Registration Number
- NCT05154240
- Locations
- π³πΏ
NZCR Ltd, Christchurch, New Zealand
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
Β© Copyright 2024. All Rights Reserved by MedPath